The M rule for primary biliary cholangitis includes the presence of IgM and anti-Mitochondrial antibodies, specifically the M2 subtype, in middle-aged women.

Primary Biliary Cholangitis: A Chronic Liver Disorder

Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a chronic liver disorder that is commonly observed in middle-aged women. The exact cause of this condition is not yet fully understood, but it is believed to be an autoimmune disease. The disease is characterized by the progressive damage of interlobular bile ducts due to chronic inflammation, leading to cholestasis and eventually cirrhosis. The most common symptom of primary biliary cholangitis is itching in middle-aged women.

This condition is often associated with other autoimmune diseases such as Sjogren’s syndrome, rheumatoid arthritis, systemic sclerosis, and thyroid disease. Early symptoms of primary biliary cholangitis may be asymptomatic or may include fatigue, pruritus, and cholestatic jaundice. Late symptoms may progress to liver failure. Diagnosis of primary biliary cholangitis involves immunology tests such as anti-mitochondrial antibodies (AMA) M2 subtype and smooth muscle antibodies, as well as imaging tests to exclude an extrahepatic biliary obstruction.

The first-line treatment for primary biliary cholangitis is ursodeoxycholic acid, which slows down the progression of the disease and improves symptoms. Cholestyramine is used to alleviate pruritus, and fat-soluble vitamin supplementation is recommended. In severe cases, liver transplantation may be necessary, especially if bilirubin levels exceed 100. However, recurrence in the graft can occur, but it is not usually a problem. Complications of primary biliary cholangitis include cirrhosis, portal hypertension, ascites, variceal hemorrhage, osteomalacia, osteoporosis, and an increased risk of hepatocellular carcinoma.

Sjögren’s Syndrome and its Ocular Manifestations

Sjögren’s syndrome is an autoimmune disease that primarily affects the exocrine glands, leading to decreased production of tears and saliva. This results in dry eyes and dry mouth, which can cause corneal abrasions and even ulceration if left untreated. It is commonly associated with connective tissue diseases, particularly rheumatoid arthritis.

When it comes to ocular manifestations, it is important to differentiate Sjögren’s syndrome from other conditions such as scleritis, episcleritis, uveitis, and ulcerative keratitis. The phenylephrine test can help distinguish between episcleritis and scleritis, while uveitis typically presents with ocular pain, photophobia, and blurred vision. Ulcerative keratitis, on the other hand, has an infectious presentation and requires different treatment approaches depending on the depth of the ulcer.

Overall, the pathophysiology and ocular manifestations of Sjögren’s syndrome is crucial for proper diagnosis and management of this autoimmune disease.

Management of Acute Asthma

Acute asthma is classified by the British Thoracic Society (BTS) into three categories: moderate, severe, and life-threatening. Patients with any of the life-threatening features should be treated as having a life-threatening attack. A fourth category, Near-fatal asthma, is also recognized. Further assessment may include arterial blood gases for patients with oxygen saturation levels below 92%. A chest x-ray is not routinely recommended unless the patient has life-threatening asthma, suspected pneumothorax, or failure to respond to treatment.

Admission criteria include a previous near-fatal asthma attack, pregnancy, an attack occurring despite already using oral corticosteroid, and presentation at night. All patients with life-threatening asthma should be admitted to the hospital, and patients with features of severe acute asthma should also be admitted if they fail to respond to initial treatment. Oxygen therapy should be started for hypoxaemic patients. Bronchodilation with short-acting beta₂-agonists (SABA) is recommended, and all patients should be given 40-50 mg of prednisolone orally daily. Ipratropium bromide and IV magnesium sulphate may also be considered for severe or life-threatening asthma. Patients who fail to respond require senior critical care support and should be treated in an appropriate ITU/HDU setting. Criteria for discharge include stability on discharge medication, checked and recorded inhaler technique, and PEF levels above 75% of best or predicted.

The patient’s symptoms indicate a life-threatening severity of asthma, as evidenced by their inability to complete full sentences and a PEFR measurement within the severe range. This is further supported by their normal pCO2 levels, which confirm the severity classification. The classification of moderate severity is incorrect in this case.

Management of Acute Asthma

Acute asthma is classified by the British Thoracic Society (BTS) into three categories: moderate, severe, and life-threatening. Patients with any of the life-threatening features should be treated as having a life-threatening attack. A fourth category, Near-fatal asthma, is also recognized. Further assessment may include arterial blood gases for patients with oxygen saturation levels below 92%. A chest x-ray is not routinely recommended unless the patient has life-threatening asthma, suspected pneumothorax, or failure to respond to treatment.

Admission criteria include a previous near-fatal asthma attack, pregnancy, an attack occurring despite already using oral corticosteroid, and presentation at night. All patients with life-threatening asthma should be admitted to the hospital, and patients with features of severe acute asthma should also be admitted if they fail to respond to initial treatment. Oxygen therapy should be started for hypoxaemic patients. Bronchodilation with short-acting beta₂-agonists (SABA) is recommended, and all patients should be given 40-50 mg of prednisolone orally daily. Ipratropium bromide and IV magnesium sulphate may also be considered for severe or life-threatening asthma. Patients who fail to respond require senior critical care support and should be treated in an appropriate ITU/HDU setting. Criteria for discharge include stability on discharge medication, checked and recorded inhaler technique, and PEF levels above 75% of best or predicted.

For patients under 65 years old with subclinical hypothyroidism and a TSH level between 5.5-10mU/L, a 6-month trial of thyroxine should be offered if they have hypothyroidism symptoms and their TSH remains elevated on two separate occasions 3 months apart. This is because subclinical hypothyroidism increases the risk of cardiovascular disease and progression to overt hypothyroidism, and treatment with levothyroxine generally resolves symptoms. Repeat thyroid autoantibody tests and thyroid function testing after 3 months are unnecessary if the patient has already had negative autoantibody results and two elevated TSH levels 3 months apart. Prescribing levothyroxine only if further symptoms develop is not recommended as it delays treatment and increases the risk of negative impacts on the patient’s quality of life.

Understanding Subclinical Hypothyroidism

Subclinical hypothyroidism is a condition where the thyroid-stimulating hormone (TSH) is elevated, but the levels of T3 and T4 are normal, and there are no obvious symptoms. However, there is a risk of the condition progressing to overt hypothyroidism, especially in men, with a 2-5% chance per year. This risk is further increased if thyroid autoantibodies are present.

Not all patients with subclinical hypothyroidism require treatment, and guidelines have been produced by NICE Clinical Knowledge Summaries (CKS) to help determine when treatment is necessary. If the TSH level is above 10mU/L and the free thyroxine level is within the normal range, levothyroxine may be offered. If the TSH level is between 5.5 – 10mU/L and the free thyroxine level is within the normal range, a 6-month trial of levothyroxine may be considered if the patient is under 65 years old and experiencing symptoms of hypothyroidism. For older patients, a ‘watch and wait’ strategy is often used, and asymptomatic patients may simply have their thyroid function monitored every 6 months.

In summary, subclinical hypothyroidism is a condition that requires careful monitoring and consideration of treatment options based on individual patient factors.

The presence of fever, headache, and a focal neurological deficit, such as arm weakness, suggests a brain abscess as the correct diagnosis. Additionally, the patient’s history of seizures supports this diagnosis. However, diagnosing a brain abscess can be challenging, as the classic triad of symptoms is only present in a minority of cases. Epilepsy is unlikely due to the presence of fever and arm weakness, and the absence of a seizure history. Hypoglycemia is not the correct answer as the patient’s blood glucose level is within the normal range. Meningitis is a key differential diagnosis, but it is less likely to cause focal neurological abnormalities and tends to present with reduced consciousness or confusion in addition to fever and headache.

Understanding Brain Abscesses

Brain abscesses can occur due to various reasons such as sepsis from middle ear or sinuses, head injuries, and endocarditis. The symptoms of brain abscesses depend on the location of the abscess, with those in critical areas presenting earlier. Brain abscesses can cause a considerable mass effect in the brain, leading to raised intracranial pressure. Symptoms of brain abscesses include dull and persistent headaches, fever, focal neurology, nausea, papilloedema, and seizures.

To diagnose brain abscesses, doctors may perform imaging with CT scanning. Treatment for brain abscesses involves surgery, where a craniotomy is performed to remove the abscess cavity. However, the abscess may reform because the head is closed following abscess drainage. Intravenous antibiotics such as 3rd-generation cephalosporin and metronidazole are also administered. Additionally, intracranial pressure management with dexamethasone may be necessary.

Overall, brain abscesses are a serious condition that requires prompt medical attention. Understanding the symptoms and treatment options can help individuals seek medical help early and improve their chances of recovery.

Alcohol can affect the way many drugs are metabolized and can alter their bioavailability. Chronic alcohol excess can cause a paradoxical induction in the cytochrome P450 enzyme system, leading to a relative reduction in bioavailability of drugs that utilize this metabolism pathway. Atorvastatin and other drugs of this class can have altered bioavailability when used with alcohol. Metronidazole can cause a disulfiram-like reaction when mixed with alcohol. Paracetamol and metformin have few interactions with alcohol but should be closely monitored in alcoholic patients.

Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) share similar features such as tremors, rigidity, postural instability, fluctuating cognition, and hallucinations. However, they can be differentiated based on the time of onset of dementia compared to motor symptoms. PDD is diagnosed if a patient had a Parkinson’s disease diagnosis for at least 1 year before the emergence of dementia. In contrast, DLB would have dementia occurring first followed by motor symptoms. This patient has had 8 years of preceding motor symptoms before the onset of dementia, making PDD more likely. It is important to distinguish between the two as their management varies significantly. Levodopa is the mainstay of treatment in PDD, whereas rivastigmine is the drug of choice in DLB. Treating this patient as DLB may miss out on important elements of treatment needed in patients with PDD. Frontotemporal dementia (FTD) and multiple system atrophy are not likely diagnoses in this case as they have different clinical features.

Understanding Lewy Body Dementia

Lewy body dementia is a type of dementia that is becoming more recognized as a cause of cognitive impairment, accounting for up to 20% of cases. It is characterized by the presence of alpha-synuclein cytoplasmic inclusions, known as Lewy bodies, in certain areas of the brain. While there is a complicated relationship between Parkinson’s disease and Lewy body dementia, with dementia often seen in Parkinson’s disease, the two conditions are distinct. Additionally, up to 40% of patients with Alzheimer’s disease have Lewy bodies.

The features of Lewy body dementia include progressive cognitive impairment, which typically occurs before parkinsonism, but both features usually occur within a year of each other. Unlike other forms of dementia, cognition may fluctuate, and early impairments in attention and executive function are more common than memory loss. Other features include parkinsonism, visual hallucinations, and sometimes delusions and non-visual hallucinations.

Diagnosis of Lewy body dementia is usually clinical, but single-photon emission computed tomography (SPECT) can be used to confirm the diagnosis. Management of Lewy body dementia involves the use of acetylcholinesterase inhibitors and memantine, similar to Alzheimer’s disease. However, neuroleptics should be avoided as patients with Lewy body dementia are extremely sensitive and may develop irreversible parkinsonism. It is important to carefully consider the use of medication in these patients to avoid worsening their condition.

A sudden decrease in haemoglobin is linked to aplastic crises in sickle cell disease. This condition is characterized by symptoms of anaemia and is often triggered by exposure to parvovirus B-19. The low reticulocyte count indicates acute bone marrow failure.

Sickle cell anaemia is a condition that involves periods of good health with intermittent crises. There are several types of crises that can occur, including thrombotic or painful crises, sequestration, acute chest syndrome, aplastic, and haemolytic. Thrombotic crisis, also known as painful crises or vaso-occlusive crises, are triggered by factors such as infection, dehydration, and deoxygenation. These crises are diagnosed clinically and can result in infarcts in various organs, including the bones, lungs, spleen, and brain.

Sequestration crises occur when sickling occurs within organs such as the spleen or lungs, leading to pooling of blood and worsening of anaemia. This type of crisis is associated with an increased reticulocyte count. Acute chest syndrome is caused by vaso-occlusion within the pulmonary microvasculature, resulting in infarction in the lung parenchyma. Symptoms include dyspnoea, chest pain, pulmonary infiltrates on chest x-ray, and low pO2. Management involves pain relief, respiratory support, antibiotics, and transfusion.

Aplastic crises are caused by infection with parvovirus and result in a sudden fall in haemoglobin. Bone marrow suppression leads to a reduced reticulocyte count. Haemolytic crises are rare and involve a fall in haemoglobin due to an increased rate of haemolysis. It is important to recognise and manage these crises promptly, as they can lead to serious complications and even death.

Understanding Henoch-Schonlein Purpura

Henoch-Schonlein purpura (HSP) is a type of small vessel vasculitis that is mediated by IgA. It is often associated with IgA nephropathy, also known as Berger’s disease. HSP is commonly observed in children following an infection.

The condition is characterized by a palpable purpuric rash, which is accompanied by localized oedema over the buttocks and extensor surfaces of the arms and legs. Other symptoms include abdominal pain, polyarthritis, and features of IgA nephropathy such as haematuria and renal failure.

Treatment for HSP involves analgesia for arthralgia, while management of nephropathy is generally supportive. There is inconsistent evidence for the use of steroids and immunosuppressants.

The prognosis for HSP is usually excellent, especially in children without renal involvement. The condition is self-limiting, but around one-third of patients may experience a relapse. It is important to monitor blood pressure and urinalysis to detect any progressive renal involvement.

Overall, understanding Henoch-Schonlein purpura is crucial for prompt diagnosis and management of the condition.

WHO Recommendations for Diabetes and Intermediate Hyperglycaemia Diagnosis

The World Health Organization (WHO) has established diagnostic criteria for diabetes and intermediate hyperglycaemia. According to the 2006 recommendations, a fasting plasma glucose level of 7.0 mmol/L (126 mg/dL) or higher, or a 2-hour plasma glucose level of 11.1 mmol/L (200 mg/dL) or higher indicates diabetes. On the other hand, impaired glucose tolerance (IGT) is diagnosed when the fasting plasma glucose level is less than 7.0 mmol/L (126 mg/dL) and the 2-hour plasma glucose level is between 7.8 and 11.1 mmol/L (140 mg/dL and 200 mg/dL). Impaired fasting glucose (IFG) is diagnosed when the fasting plasma glucose level is between 6.1 and 6.9 mmol/L (110 mg/dL to 125 mg/dL) and the 2-hour plasma glucose level is less than 7.8 mmol/L (140 mg/dL), if measured.

It is important to note that if the 2-hour plasma glucose level is not measured, the status of the individual is uncertain as diabetes or IGT cannot be excluded. These recommendations serve as a guide for healthcare professionals in diagnosing and managing diabetes and intermediate hyperglycaemia.

Parvovirus can be indicated by a sudden onset of anemia and a low reticulocyte count, while a high reticulocyte count may be caused by acute sequestration and hemolysis.

Sickle-cell anaemia is a genetic disorder that occurs when abnormal haemoglobin, known as HbS, is produced due to an autosomal recessive condition. This condition is more common in individuals of African descent, as the heterozygous condition provides some protection against malaria. About 10% of UK Afro-Caribbean are carriers of HbS, and they only experience symptoms if they are severely hypoxic. Homozygotes tend to develop symptoms between 4-6 months when the abnormal HbSS molecules replace fetal haemoglobin.

The pathophysiology of sickle-cell anaemia involves the substitution of the polar amino acid glutamate with the non-polar valine in each of the two beta chains (codon 6) of haemoglobin. This substitution decreases the water solubility of deoxy-Hb, causing HbS molecules to polymerise and sickle RBCs in the deoxygenated state. HbAS patients sickle at p02 2.5 – 4 kPa, while HbSS patients sickle at p02 5 – 6 kPa. Sickle cells are fragile and haemolyse, blocking small blood vessels and causing infarction.

The definitive diagnosis of sickle-cell anaemia is through haemoglobin electrophoresis.

Acute kidney injury (AKI) is a condition where there is a sudden decrease in kidney function, which can be defined by a decrease in glomerular filtration rate (GFR) or a decrease in urine output. AKI can be caused by various factors such as prerenal, renal, or postrenal causes. Medications can also cause AKI, and caution should be taken when prescribing ACE inhibitors to patients with declining renal function. In the event of an AKI, certain medications such as ACE inhibitors, A2RBs, NSAIDs, diuretics, aminoglycosides, metformin, and lithium should be temporarily discontinued. Atorvastatin and bisoprolol are safe to prescribe in patients with kidney disease, while finasteride and tamsulosin can be prescribed for benign prostatic hyperplasia but should be used with caution in patients with poor renal function.

Understanding Acute Kidney Injury: A Basic Overview

Acute kidney injury (AKI) is a condition where the kidneys experience a reduction in function due to an insult. In the past, the kidneys were often neglected in acute medicine, resulting in slow recognition and limited action. However, around 15% of patients admitted to the hospital develop AKI. While most patients recover their renal function, some may have long-term impaired kidney function due to AKI, which can result in acute complications, including death. Identifying patients at increased risk of AKI is crucial in reducing its incidence. Risk factors for AKI include chronic kidney disease, other organ failure/chronic disease, a history of AKI, and the use of drugs with nephrotoxic potential.

AKI has three main causes: prerenal, intrinsic, and postrenal. Prerenal causes are due to a lack of blood flow to the kidneys, while intrinsic causes relate to intrinsic damage to the kidneys themselves. Postrenal causes occur when there is an obstruction to the urine coming from the kidneys. Symptoms of AKI include reduced urine output, fluid overload, arrhythmias, and features of uraemia. Diagnosis of AKI is made through blood tests, urinalysis, and imaging.

The management of AKI is largely supportive, with careful fluid balance and medication review being crucial. Loop diuretics and low-dose dopamine are not recommended, but hyperkalaemia needs prompt treatment to avoid life-threatening arrhythmias. Renal replacement therapy may be necessary in severe cases. Prompt review by a urologist is required for patients with suspected AKI secondary to urinary obstruction, while specialist input from a nephrologist is necessary for cases where the cause is unknown or the AKI is severe.

Understanding Fourth Nerve Palsy

Fourth nerve palsy is a condition that affects the superior oblique muscle, which is responsible for depressing the eye and moving it inward. One of the main features of this condition is vertical diplopia, which is the perception of seeing two images stacked on top of each other. This is often noticed when reading a book or going downstairs. Another symptom is subjective tilting of objects, also known as torsional diplopia. Patients may also develop a head tilt, which they may or may not be aware of. When looking straight ahead, the affected eye appears to deviate upwards and is rotated outwards. Understanding these symptoms can help with early diagnosis and treatment of fourth nerve palsy.

If a patient with distal ulcerative colitis experiences a mild-moderate flare that does not respond to topical aminosalicylates, oral aminosalicylates should be added as an adjunct therapy. In this case, the patient’s symptoms are typical of a mild flare according to Truelove and Witt’s criteria. As his symptoms are not improving with topical treatment, oral mesalazine should be added while continuing the topical mesalazine. Oral steroids are not currently indicated for this patient’s mild flare. It is important to continue the topical therapy alongside the oral therapy for optimal management. If symptoms do not improve within two weeks, the patient should schedule a follow-up appointment.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools and presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Extensive disease may require a high-dose oral aminosalicylate and topical treatment. Severe colitis should be treated in a hospital with intravenous steroids or ciclosporin. Maintaining remission can involve using a low maintenance dose of an oral aminosalicylate or oral azathioprine/mercaptopurine. Methotrexate is not recommended, but probiotics may prevent relapse in mild to moderate cases.

Association Neurones and neuroglial Cells in the Central Nervous System

Association neurones are present in the central nervous system and their primary function is to connect afferent neurones that bring information into the central nervous system to efferent neurones that carry information away from the central nervous system. Afferent neurones are responsible for transmitting sensory information from peripheral receptors to the central nervous system, while efferent neurones transmit motor information from the central nervous system to effectors such as muscles or glands.

In addition to neurones, the nervous system also contains neuroglial cells. These non-neuronal cells provide support and nutrition to the nervous system. neuroglial cells are essential for the proper functioning of the nervous system and play a crucial role in maintaining the health of neurones.

the role of association neurones and neuroglial cells is essential for comprehending the functioning of the central nervous system. These cells work together to ensure that the nervous system can receive and transmit information effectively. By studying these cells, researchers can gain insights into the mechanisms underlying various neurological disorders and develop new treatments to address them.

If the patient’s oxygen saturation levels remain low, administering high flow oxygen would not be appropriate as it is not an emergency situation. Instead, it would be more reasonable to begin with 1-2L of oxygen and reevaluate the need for further oxygen therapy, as weaning off oxygen could potentially prolong the patient’s hospital stay.

Atelectasis is a frequent complication that can occur after surgery, where the collapse of the alveoli in the lower part of the lungs can cause breathing difficulties. This condition is caused by the blockage of airways due to the accumulation of bronchial secretions. Symptoms of atelectasis may include shortness of breath and low oxygen levels, which typically appear around 72 hours after surgery. To manage this condition, patients may be positioned upright and undergo chest physiotherapy, which includes breathing exercises.

Patients with cancer have a high risk of developing hypercalcemia, which is linked to a shortened QT interval. The QT interval can also be prolonged due to electrolyte imbalances such as hypokalemia, hypomagnesemia, and hypocalcemia, as well as hypothermia, myocardial ischemia, and congenital long QT syndrome. First-degree heart block is characterized by a fixed prolonged PR interval, while hyperkalemia is indicated by tall T waves that may be followed by flattened P waves, PR prolongation, and a sine-wave appearance. S1Q3T3, which refers to an S wave in lead I, a Q wave in lead III, and an inverted T wave in lead III, is a rare finding that is often associated with pulmonary embolism (PE), but it is not a reliable indicator of this condition.

Hypercalcaemia: Symptoms and Signs

Hypercalcaemia is a medical condition characterized by high levels of calcium in the blood. The symptoms and signs of hypercalcaemia can be remembered by the phrase ‘bones, stones, groans and psychic moans’. This means that patients with hypercalcaemia may experience bone pain, kidney stones, constipation, and changes in mood or behavior. In addition, corneal calcification and a shortened QT interval on an electrocardiogram (ECG) may also be present. Hypertension, or high blood pressure, is another common feature of hypercalcaemia. It is important to seek medical attention if any of these symptoms are present, as hypercalcaemia can lead to serious complications if left untreated.

Distinguishing between pseudoseizures and true seizures can be challenging as they share some similarities. However, one key difference is that pseudoseizures tend to have a gradual onset, while true seizures have a sudden onset. Pseudoseizures are often linked to psychiatric conditions and are not voluntary, but rather compulsive and unwanted movements. It is common for individuals experiencing pseudoseizures to have some control over the location of their symptoms. While dystonia may involve shaking, it typically results in rigidity rather than gradual onset and offset.

Understanding Psychogenic Non-Epileptic Seizures

Psychogenic non-epileptic seizures, also known as pseudoseizures, are a type of seizure that is not caused by abnormal electrical activity in the brain. Instead, they are believed to be caused by psychological factors such as stress, trauma, or anxiety. These seizures can be difficult to diagnose as they often mimic true epileptic seizures, but there are certain factors that can help differentiate between the two.

Factors that may indicate pseudoseizures include pelvic thrusting, a family history of epilepsy, a higher incidence in females, crying after the seizure, and the seizures not occurring when the individual is alone. On the other hand, factors that may indicate true epileptic seizures include tongue biting and a raised serum prolactin level.

Video telemetry is a useful tool for differentiating between the two types of seizures. It involves monitoring the individual’s brain activity and behavior during a seizure, which can help determine whether it is caused by abnormal electrical activity in the brain or psychological factors.

It is important to accurately diagnose and treat psychogenic non-epileptic seizures as they can have a significant impact on an individual’s quality of life. Treatment may involve therapy to address underlying psychological factors, as well as medication to manage any associated symptoms such as anxiety or depression.

If the HbA1c level in type 2 diabetes mellitus is above 58 mmol/mol, a second drug should be added.

When a patient’s HbA1c result indicates poor glucose control, it may be due to various factors such as tolerance, adherence, or lifestyle issues. In such cases, the next step is to prescribe a second medication, which could be a DPP-4 inhibitor, sulfonylurea, or SGLT-2 inhibitor, based on the patient’s needs and after weighing the risks and benefits of each option.

The standard dose of metformin is 500g daily, which can be increased up to a maximum of 2g daily, divided into separate doses. However, if the patient is already on 2g, the dose cannot be increased further. Thiazolidinediones like pioglitazone are not recommended for patients with heart failure and are rarely used as first or second-line therapies.

Since the patient’s HbA1c levels exceed 58 mmol/mol, an additional intervention is necessary, along with reinforcing lifestyle and dietary advice. Insulin is typically reserved for patients who do not respond to double or triple therapy.

NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022, reflecting advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. The first-line drug of choice remains metformin, which should be titrated up slowly to minimize gastrointestinal upset. HbA1c targets should be agreed upon with patients and checked every 3-6 months until stable, with consideration for relaxing targets on a case-by-case basis. Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates and controlling intake of foods containing saturated fats and trans fatty acids. Blood pressure targets are the same as for patients without type 2 diabetes, and antiplatelets should not be offered unless a patient has existing cardiovascular disease. Only patients with a 10-year cardiovascular risk > 10% should be offered a statin, with atorvastatin 20 mg as the first-line choice.